Oncternal Therapeutics to Participate in September Investor Conferences
Oncternal Therapeutics, a clinical-stage biopharmaceutical company focused on oncology, will participate in three virtual conferences in September 2021. The events include the H.C. Wainwright 23rd Annual Global Investment Conference on September 13 at 7:00 am ET, the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 22 at 11:35 am ET, and the Cantor Global Healthcare Conference on September 29 at 11:20 am ET. Webcasts and replays will be available on their investor page.
- None.
- None.
SAN DIEGO, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that management will participate in the following conferences in the month of September:
- H.C. Wainwright 23rd Annual Global Investment Conference (Virtual) on Monday, September 13 at 7:00am ET
- Oppenheimer Fall Healthcare Life Sciences & MedTech Summit (Virtual) on Wednesday, September 22 at 11:35am ET
- Cantor Global Healthcare Conference (Virtual) on Wednesday, September 29 at 11:20am ET
Links to the webcasts along with replays will be accessible on the Events & Presentations page of the Investors section on the Company’s website at investor.oncternal.com.
About Oncternal Therapeutics
Oncternal Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. Oncternal focuses drug development on promising, yet untapped biological pathways implicated in cancer generation or progression. The clinical pipeline includes cirmtuzumab, an investigational monoclonal antibody designed to inhibit the ROR1 pathway, a type I tyrosine kinase-like orphan receptor, that is being evaluated in a Phase 1/2 clinical trial in combination with ibrutinib for the treatment of patients with mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL) and in an investigator-sponsored, Phase 1b clinical trial in combination with paclitaxel for the treatment of women with HER2-negative metastatic or locally advanced, unresectable breast cancer, as well as a Phase 2 clinical trial of cirmtuzumab in combination with venetoclax, a Bcl-2 inhibitor, in patients with relapsed/refractory CLL. Oncternal is also developing a chimeric antigen receptor T cell (CAR-T) therapy that targets ROR1, which is currently in preclinical development as a potential treatment for hematologic cancers and solid tumors. The clinical pipeline also includes TK216, an investigational targeted small-molecule inhibitor of the ETS family of oncoproteins, that is being evaluated in a Phase 1/2 clinical trial for patients with Ewing sarcoma alone and in combination with vincristine chemotherapy. More information is available at https://oncternal.com.
Contact information:
Investors
Richard Vincent
Chief Financial Officer
858-434-1113
rvincent@oncternal.com
Media
Corey Davis
LifeSci Advisors
212-915-2577
cdavis@lifesciadvisors.com
FAQ
What conferences is Oncternal participating in September 2021?
When is the H.C. Wainwright Conference for Oncternal?
Where can I find Oncternal's conference webcasts?
What is Oncternal's focus in oncology?
What is the ticker symbol for Oncternal Therapeutics?
